Edition:
United Kingdom

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

38.68USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$38.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
206,120
52-wk High
$73.90
52-wk Low
$22.23

Cagnoni, Pablo 

Dr. Pablo J. Cagnoni, M.D., has been Independent Director of CRISPR Therapeutics Ltd since December 2015. He is currently the President and CEO of Tizona Therapeutics and Managing Director of MPM Capital. Most recently, he served as President of Onyx Pharmaceuticals where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSIPharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from the University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni is currently on the board of directors of Harpoon Therapeutics and he is Executive Chairman of Blade Therapeutics, both private biotechnology companies.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --